CBDNUTRITIONAL.COM ORGANIC HEMPCBD PRODUCTS
  • home
  • ORDER HERE
  • CBD STORE AZ
  • consultation
  • QUALITY CONTROL
  • CBD Life Blog
  • Cbd health studies
  • CBD FAQ's
    • KNOW YOUR SOURCE/SUPPLIER
    • DOSING
    • Endocannabinoid Deficiency Theory
    • Hemp Cannabinoids & Terpenes
    • CBG
    • CBD Glossary
    • Full Spectrum vs Isolate
    • Topical ? Transdermal ?
    • Vaping Pure CBD
    • Smoking Hemp Flower
    • Cannabinoid Drug Interaction
    • CBD & Pets
    • CBD for Anxiety
    • CBD for Depression
    • CBD for Diabetes
    • CBD FOR WELLNESS
    • CBD 4 BEAUTY
  • Wellness Beyond CBD
    • Anti-Aging CBD
    • EMF PROTECTION
    • NUTRITION FOR WELLNESS
    • EXERCISE FOR WELLNESS
  • Website Policy
    • Terms and Conditions
    • Privacy Policy
  • Current CBD News

CBD Life Blog

Study: CBD May be Effective in the Treatment of Painful Diabetic Neuropathy

4/1/2019

0 Comments

 
“Most diabetic patients describe moderate to severe pain symptoms whose pharmacological treatment is palliative and poorly effective”, states the study’s abstract. “Cannabidiol (CBD) has shown promising results in painful conditions.” With this in mind, researchers “aimed to investigate the potential antinociceptive effect of CBD over the mechanical allodynia in streptozotocin-induced diabetic (DBT) rats, as well as its involved mechanisms.”

For the study, “Wistar adult male diabetic rats were treated acutely or sub-chronically (for 14 days) with CBD (0.1, 0.3 or 3 mg/Kg, intraperitoneal; i.p.) and had their mechanical threshold assessed using the electronic Von Frey. ” Acute treatment with CBD (at doses of 0.3 and 3 mg/Kg) “exerted a significant anti-allodynic effect, which is not associated with locomotor impairment. “The antinociceptive effect of CBD (3 mg/Kg) was not altered by the pre-treatment with CB1 or CB2 receptor antagonists (AM251 and AM630; respectively; both at a dose of 1 mg/kg, i.p.) nor by glycine receptor antagonist (strychnine hydrochloride, 10 μg/rat, intrathecal, i.t.).”

“However,”  the study states, “this effect was completely prevented by the pre-treatment with the selective 5-HT1A receptor antagonist WAY 100135 (3 μg/rat, i.t.). Sub-chronic treatment with CBD (0.3 or 3 mg/Kg) induced a sustained attenuation of the mechanical allodynia in DBT rats.”

DBT rats “presented significantly lower spinal cord levels of serotonin, which was prevented by the daily treatment with CBD (0.3 mg/Kg).”

Taken together, the data “suggest that CBD may be effective in the treatment of painful diabetic neuropathy and this effect seems to be potentially mediated by the serotonergic system activation through 5-HT1A receptors.”

The full abstract can be found below:

Most diabetic patients describe moderate to severe pain symptoms whose pharmacological treatment is palliative and poorly effective. Cannabidiol (CBD) has shown promising results in painful conditions. Then, we aimed to investigate the potential antinociceptive effect of CBD over the mechanical allodynia in streptozotocin-induced diabetic (DBT) rats, as well as its involved mechanisms. Wistar adult male diabetic rats were treated acutely or sub-chronically (for 14 days) with CBD (0.1, 0.3 or 3 mg/Kg, intraperitoneal; i.p.) and had their mechanical threshold assessed using the electronic Von Frey. Acute treatment with CBD (at doses of 0.3 and 3 mg/Kg) exerted a significant anti-allodynic effect, which is not associated with locomotor impairment. The antinociceptive effect of CBD (3 mg/Kg) was not altered by the pre-treatment with CB1 or CB2 receptor antagonists (AM251 and AM630; respectively; both at a dose of 1 mg/kg, i.p.) nor by glycine receptor antagonist (strychnine hydrochloride, 10 μg/rat, intrathecal, i.t.). However, this effect was completely prevented by the pre-treatment with the selective 5-HT1A receptor antagonist WAY 100135 (3 μg/rat, i.t.). Sub-chronic treatment with CBD (0.3 or 3 mg/Kg) induced a sustained attenuation of the mechanical allodynia in DBT rats. DBT rats presented significantly lower spinal cord levels of serotonin, which was prevented by the daily treatment with CBD (0.3 mg/Kg). Taken together, our data suggest that CBD may be effective in the treatment of painful diabetic neuropathy and this effect seems to be potentially mediated by the serotonergic system activation through 5-HT1A receptors.
​

This abstract, and a link to the full text, can be found on the National Institute of Health’s website at the following link: https://www.ncbi.nlm.nih.gov/pubmed/30898678

0 Comments



Leave a Reply.

    Author

    Hi I'm Chris and I thought it was time I should start writing about living with CBD.  So here goes!  5/17

    Archives

    October 2022
    September 2022
    July 2021
    October 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    October 2019
    September 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    December 2018
    October 2018
    September 2018
    August 2018
    July 2018
    May 2018
    April 2018
    March 2018
    January 2018
    July 2017
    June 2017
    May 2017

    Categories

    All

    RSS Feed

Powered by Create your own unique website with customizable templates.
  • home
  • ORDER HERE
  • CBD STORE AZ
  • consultation
  • QUALITY CONTROL
  • CBD Life Blog
  • Cbd health studies
  • CBD FAQ's
    • KNOW YOUR SOURCE/SUPPLIER
    • DOSING
    • Endocannabinoid Deficiency Theory
    • Hemp Cannabinoids & Terpenes
    • CBG
    • CBD Glossary
    • Full Spectrum vs Isolate
    • Topical ? Transdermal ?
    • Vaping Pure CBD
    • Smoking Hemp Flower
    • Cannabinoid Drug Interaction
    • CBD & Pets
    • CBD for Anxiety
    • CBD for Depression
    • CBD for Diabetes
    • CBD FOR WELLNESS
    • CBD 4 BEAUTY
  • Wellness Beyond CBD
    • Anti-Aging CBD
    • EMF PROTECTION
    • NUTRITION FOR WELLNESS
    • EXERCISE FOR WELLNESS
  • Website Policy
    • Terms and Conditions
    • Privacy Policy
  • Current CBD News